Advances in Targeted Therapies for Triple-Negative Breast Cancer

被引：72

作者：

McCann, Kelly E. ^{[1
]}

Hurvitz, Sara A. ^{[1
]}

McAndrew, Nicholas ^{[1
]}

机构：

[1] Univ Calif Los Angeles, David Geffen Sch Med, Dept Med, Div Hematol Oncol, 2336 Santa Monica,Suite 304, Los Angeles, CA 90404 USA

来源：

DRUGS | 2019年 / 79卷 / 11期

关键词：

SACITUZUMAB GOVITECAN; 1ST-LINE THERAPY; DOUBLE-BLIND; PARP; INHIBITOR; PALBOCICLIB; FULVESTRANT; SUBTYPES; AKT; IMMUNOTHERAPY;

D O I：

10.1007/s40265-019-01155-4

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

While the outcomes for patients diagnosed with hormone receptor positive (HR+) and/or human epidermal growth factor receptor 2-positive (HER2+) breast cancers have continued to improve with the development of targeted therapies, the same cannot be said yet for those affected with triple-negative breast cancer (TNBC). Currently, the mainstay of treatment for the 10- 15% of patients diagnosed with TNBC remains cytotoxic chemotherapy, but it is hoped that through an enhanced characterization of TNBC biology, this disease will be molecularly delineated into subgroups with targetable oncogenic drivers. This review will focus on recent therapeutic innovations for TNBC, including poly-ADP-ribosyl polymerase (PARP) inhibitors, phosphoinositide 3-kinase (PI3K) pathway inhibitors, immune checkpoint inhibitors, and cyclin-dependent kinase (CDK) inhibitors.

引用

页码：1217 / 1230

页数：14

共 67 条

[31] Ipatasertib plus paclitaxel versus placebo plus paclitaxel as first-line therapy for metastatic triple-negative breast cancer (LOTUS): a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial [J].

Kim, Sung-Bae ;

Dent, Rebecca ;

Im, Seock-Ah ;

Espie, Marc ;

Blau, Sibel ;

Tan, Antoinette R. ;

Isakoff, Steven J. ;

Oliveira, Mafalda ;

Saura, Cristina ;

Wongchenko, Matthew J. ;

Kapp, Amy V. ;

Chan, Wai Y. ;

Singel, Stina M. ;

Maslyar, Daniel J. ;

Baselga, Jose .

LANCET ONCOLOGY, 2017, 18 (10) :1360-1372

[32] Comprehensive molecular portraits of human breast tumours [J].

Koboldt, Daniel C. ;

Fulton, Robert S. ;

McLellan, Michael D. ;

Schmidt, Heather ;

Kalicki-Veizer, Joelle ;

McMichael, Joshua F. ;

Fulton, Lucinda L. ;

Dooling, David J. ;

Ding, Li ;

Mardis, Elaine R. ;

Wilson, Richard K. ;

Ally, Adrian ;

Balasundaram, Miruna ;

Butterfield, Yaron S. N. ;

Carlsen, Rebecca ;

Carter, Candace ;

Chu, Andy ;

Chuah, Eric ;

Chun, Hye-Jung E. ;

Coope, Robin J. N. ;

Dhalla, Noreen ;

Guin, Ranabir ;

Hirst, Carrie ;

Hirst, Martin ;

Holt, Robert A. ;

Lee, Darlene ;

Li, Haiyan I. ;

Mayo, Michael ;

Moore, Richard A. ;

Mungall, Andrew J. ;

Pleasance, Erin ;

Robertson, A. Gordon ;

Schein, Jacqueline E. ;

Shafiei, Arash ;

Sipahimalani, Payal ;

Slobodan, Jared R. ;

Stoll, Dominik ;

Tam, Angela ;

Thiessen, Nina ;

Varhol, Richard J. ;

Wye, Natasja ;

Zeng, Thomas ;

Zhao, Yongjun ;

Birol, Inanc ;

Jones, Steven J. M. ;

Marra, Marco A. ;

Cherniack, Andrew D. ;

Saksena, Gordon ;

Onofrio, Robert C. ;

Pho, Nam H. .

NATURE, 2012, 490 (7418) :61-70

[33]

Kotz J., 2012, SCI BUS EXCHANGE, V5, P323

[34] PARP goes transcription [J].

Kraus, WL ;

Lis, JT .

CELL, 2003, 113 (06) :677-683

[35] Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies [J].

Lehmann, Brian D. ;

Bauer, Joshua A. ;

Chen, Xi ;

Sanders, Melinda E. ;

Chakravarthy, A. Bapsi ;

Shyr, Yu ;

Pietenpol, Jennifer A. .

JOURNAL OF CLINICAL INVESTIGATION, 2011, 121 (07) :2750-2767

[36] Significantly upregulated TACSTD2 and Cyclin D1 correlate with poor prognosis of invasive ductal breast cancer [J].

Lin, Hong ;

Huang, Jian-Fei ;

Qiu, Jin-Rong ;

Zhang, Hui-Lin ;

Tang, Xiao-Jun ;

Li, Hu ;

Wang, Chang-Jun ;

Wang, Zhong-Can ;

Feng, Zhen-Qing ;

Zhu, Jin .

EXPERIMENTAL AND MOLECULAR PATHOLOGY, 2013, 94 (01) :73-78

[37] Targeting Activated Akt with GDC-0068, a Novel Selective Akt Inhibitor That Is Efficacious in Multiple Tumor Models [J].

Lin, Jie ;

Sampath, Deepak ;

Nannini, Michelle A. ;

Lee, Brian B. ;

Degtyarev, Michael ;

Oeh, Jason ;

Savage, Heidi ;

Guan, Zhengyu ;

Hong, Rebecca ;

Kassees, Robert ;

Lee, Leslie B. ;

Risom, Tyler ;

Gross, Stefan ;

Liederer, Bianca M. ;

Koeppen, Hartmut ;

Skelton, Nicholas J. ;

Wallin, Jeffrey J. ;

Belvin, Marcia ;

Punnoose, Elizabeth ;

Friedman, Lori S. ;

Lin, Kui .

CLINICAL CANCER RESEARCH, 2013, 19 (07) :1760-1772

[38] From Polypharmacology to Target Specificity: The Case of PARP Inhibitors [J].

Liscio, Paride ;

Camaioni, Emidio ;

Carotti, Andrea ;

Pellicciari, Roberto ;

Macchiarulo, Antonio .

CURRENT TOPICS IN MEDICINAL CHEMISTRY, 2013, 13 (23) :2939-2954

[39] Talazoparib in Patients with Advanced Breast Cancer and a Germline BRCA Mutation [J].

Litton, Jennifer K. ;

Rugo, Hope S. ;

Ettl, Johannes ;

Hurvitz, Sara A. ;

Goncalves, Anthony ;

Lee, Kyung-Hun ;

Fehrenbacher, Louis ;

Yerushalmi, Rinat ;

Mina, Lida A. ;

Martin, Miguel ;

Roche, Henri ;

Im, Young-Hyuck ;

Quek, Ruben G. W. ;

Markova, Denka ;

Tudor, Iulia C. ;

Hannah, Alison L. ;

Eiermann, Wolfgang ;

Blum, Joanne L. .

NEW ENGLAND JOURNAL OF MEDICINE, 2018, 379 (08) :753-763

[40] Addition of the PARP inhibitor veliparib plus carboplatin or carboplatin alone to standard neoadjuvant chemotherapy in triple-negative breast cancer (BrighTNess): a randomised, phase 3 trial [J].

Loibl, Sibylle ;

O'Shaughnessy, Joyce ;

Untch, Michael ;

Sikov, William M. ;

Rugo, Hope S. ;

McKee, Mark D. ;

Huober, Jens ;

Golshan, Mehra ;

von Minckwitz, Gunter ;

Maag, David ;

Sullivan, Danielle ;

Wolmark, Norman ;

McIntyre, Kristi ;

Lorenzo, Jose J. Ponce ;

Metzger Filho, Otto ;

Rastogi, Priya ;

Symmans, W. Fraser ;

Liu, Xuan ;

Geyer, Charles E., Jr. .

LANCET ONCOLOGY, 2018, 19 (04) :497-509

← 1 2 3 4 5 6 7 →